CAS: 912444-00-9; (R)-2-(2-Methylpyrrolidin-2-yl)-1H-Benzo[d]Imidazole-7-Carboxamide

该化合物是一个小分子抑制剂,主要针对DNA修复过程中涉及的酶聚(ADP-ribose)聚合酶(PARP),其化学配方为C19H22N4O3, 被归类为苯并胺衍生物;Veliparib具有诸如白到白的,有中度溶解有机溶剂的致白固体等特征;主要调查其在癌症治疗中的潜力,特别是DNA修复机制缺陷的肿瘤,如BRCA突变.Veliparib通过抑制PARP, 增强DNA降解剂的细胞毒性效应,使其成为综合肿瘤治疗的候选.该物质经过了各种临床试验,以评估其治疗不同类型癌症(包括乳腺癌和卵巢癌)的功效和安全状况.与许多药剂一样,其使用可能与副作用有关,这些作用在治疗中非常重要.

结构式图片

欧盟法规

ECHA物质C&L通报

上下游产品

veliparib (R)-2-benzyl 1-tert-butyl 2-methylpyrrolidine-1,2-dicarboxylate (R)-1-(tert-butoxycarbonyl)-2-methylpyrrolidine-2-carboxylic acid (R)-2-Methyl-1-azacyclopentan-2-carbonsaeure

合成工艺路线路线简述

  • 912444-73-6 = 912444-00-9
    反应条件:1.1 Reagents: Hydrogen Catalysts: Palladium Solvents: Methanol; 3 H,207 Kpa,Rt
    标题:Improved Synthesis Of Parp Antagonist Veliparib
    作者:Lu,Tian-Xiang; Et Al
    参考文献:Zhongguo Yaowu Huaxue Zazhi 日期:2013 卷标:23(6) 页码:476-479]

    2138822-54-3 = 912444-00-9
    反应条件:1.1 Reagents: Acetic Acid; 2 H,Reflux; Cooled1.2 Reagents: Water2.1 Reagents: Hydrogen Catalysts: Palladium Solvents: Methanol; 3 H,207 Kpa,Rt
    标题:Improved Synthesis Of Parp Antagonist Veliparib
    作者:Lu,Tian-Xiang; Et Al
    参考文献:Zhongguo Yaowu Huaxue Zazhi 日期:2013 卷标:23(6) 页码:476-479]

    606-18-8 = 912444-00-9
    反应条件:1.1 Reagents: Thionyl Chloride Solvents: 1,2-Dimethoxyethane; Rt; Overnight,Rt1.2 Reagents: Ammonium Hydroxide Solvents: Water; Cooled; 5 H,52 °C1.3 Reagents: Water; Cooled2.1 Reagents: Hydrogen Catalysts: Palladium Solvents: Methanol; 276 Kpa,Rt3.1 Reagents: Pyridine,1,1′-Carbonyldiimidazole Solvents: Dimethylformamide; 2 H,45 °C3.2 Rt3.3 Reagents: Sodium Bicarbonate Solvents: Water4.1 Reagents: Acetic Acid; 2 H,Reflux; Cooled4.2 Reagents: Water5.1 Reagents: Hydrogen Catalysts: Palladium Solvents: Methanol; 3 H,207 Kpa,Rt
    标题:Improved Synthesis Of Parp Antagonist Veliparib
    作者:Lu,Tian-Xiang; Et Al
    参考文献:Zhongguo Yaowu Huaxue Zazhi 日期:2013 卷标:23(6) 页码:476-479]

    1286768-32-8 = 912444-00-9
    反应条件:1.1 Reagents: Sodium Bicarbonate Solvents: 1,4-Dioxane,Water; Cooled; 2 H,Cooled; Overnight,Rt2.1 Reagents: Sodium Hydroxide Solvents: Methanol,Water; 2 H,Reflux; Reflux -> Rt2.2 Reagents: Hydrochloric Acid Solvents: Water; Ph 13.1 Reagents: Pyridine,1,1′-Carbonyldiimidazole Solvents: Dimethylformamide; 2 H,45 °C3.2 Rt3.3 Reagents: Sodium Bicarbonate Solvents: Water4.1 Reagents: Acetic Acid; 2 H,Reflux; Cooled4.2 Reagents: Water5.1 Reagents: Hydrogen Catalysts: Palladium Solvents: Methanol; 3 H,207 Kpa,Rt
    标题:Improved Synthesis Of Parp Antagonist Veliparib
    作者:Lu,Tian-Xiang; Et Al
    参考文献:Zhongguo Yaowu Huaxue Zazhi 日期:2013 卷标:23(6) 页码:476-479]

    1330286-50-4 = 912444-00-9
    反应条件:1.1 Reagents: Lithium Diisopropylamide Solvents: Tetrahydrofuran; -78 °C; 4 H,-78 °C; -78 °C -> Rt1.2 Reagents: Water2.1 Reagents: Thionyl Chloride; Cooled; 20 Min,Rt; 3 H,Reflux3.1 Reagents: Sodium Bicarbonate Solvents: 1,4-Dioxane,Water; Cooled; 2 H,Cooled; Overnight,Rt4.1 Reagents: Sodium Hydroxide Solvents: Methanol,Water; 2 H,Reflux; Reflux -> Rt4.2 Reagents: Hydrochloric Acid Solvents: Water; Ph 15.1 Reagents: Pyridine,1,1′-Carbonyldiimidazole Solvents: Dimethylformamide; 2 H,45 °C5.2 Rt5.3 Reagents: Sodium Bicarbonate Solvents: Water6.1 Reagents: Acetic Acid; 2 H,Reflux; Cooled6.2 Reagents: Water7.1 Reagents: Hydrogen Catalysts: Palladium Solvents: Methanol; 3 H,207 Kpa,Rt
    标题:Improved Synthesis Of Parp Antagonist Veliparib
    作者:Lu,Tian-Xiang; Et Al
    参考文献:Zhongguo Yaowu Huaxue Zazhi 日期:2013 卷标:23(6) 页码:476-479]

    = 912444-00-9 [标题:Reaction Conditions
    标题:Co-Encapsulation Of Methylene Blue And Parp-Inhibitor Into Poly(Lactic-Co-Glycolic Acid) Nanoparticles For Enhanced Pdt Of Cancer
    作者:Magalhaes,Jessica A.; Et Al
    参考文献:Nanomaterials 日期:2021 卷标:11(6)]

    = 912444-00-9 [标题:Reaction Conditions
    标题:Synthesis Of (R)-Boc-2-Methylproline Via A Memory Of Chirality Cyclization. Application To The Synthesis Of Veliparib,A Poly(Adp-Ribose) Polymerase Inhibitor
    作者:Kolaczkowski,Lawrence; Et Al
    参考文献:Journal Of Organic Chemistry 日期:2019 卷标:84(8) 页码:4837-4845]

    313279-12-8 = 912444-00-9
    反应条件:1.1 Reagents: Hydrogen Catalysts: Palladium Solvents: Methanol; 276 Kpa,Rt2.1 Reagents: Pyridine,1,1′-Carbonyldiimidazole Solvents: Dimethylformamide; 2 H,45 °C2.2 Rt2.3 Reagents: Sodium Bicarbonate Solvents: Water3.1 Reagents: Acetic Acid; 2 H,Reflux; Cooled3.2 Reagents: Water4.1 Reagents: Hydrogen Catalysts: Palladium Solvents: Methanol; 3 H,207 Kpa,Rt
    标题:Improved Synthesis Of Parp Antagonist Veliparib
    作者:Lu,Tian-Xiang; Et Al
    参考文献:Zhongguo Yaowu Huaxue Zazhi 日期:2013 卷标:23(6) 页码:476-479]

    63399-74-6 + 711007-44-2 = 912444-00-9
    反应条件:1.1 Reagents: Pyridine,1,1′-Carbonyldiimidazole Solvents: Dimethylformamide; 2 H,45 °C1.2 Rt1.3 Reagents: Sodium Bicarbonate Solvents: Water2.1 Reagents: Acetic Acid; 2 H,Reflux; Cooled2.2 Reagents: Water3.1 Reagents: Hydrogen Catalysts: Palladium Solvents: Methanol; 3 H,207 Kpa,Rt
    标题:Improved Synthesis Of Parp Antagonist Veliparib
    作者:Lu,Tian-Xiang; Et Al
    参考文献:Zhongguo Yaowu Huaxue Zazhi 日期:2013 卷标:23(6) 页码:476-479]

    1358782-60-1 = 912444-00-9
    反应条件:1.1 Reagents: Sodium Hydroxide Solvents: Methanol,Water; 2 H,Reflux; Reflux -> Rt1.2 Reagents: Hydrochloric Acid Solvents: Water; Ph 12.1 Reagents: Pyridine,1,1′-Carbonyldiimidazole Solvents: Dimethylformamide; 2 H,45 °C2.2 Rt2.3 Reagents: Sodium Bicarbonate Solvents: Water3.1 Reagents: Acetic Acid; 2 H,Reflux; Cooled3.2 Reagents: Water4.1 Reagents: Hydrogen Catalysts: Palladium Solvents: Methanol; 3 H,207 Kpa,Rt
    标题:Improved Synthesis Of Parp Antagonist Veliparib
    作者:Lu,Tian-Xiang; Et Al
    参考文献:Zhongguo Yaowu Huaxue Zazhi 日期:2013 卷标:23(6) 页码:476-479]

    1358782-55-4 = 912444-00-9
    反应条件:1.1 Reagents: Thionyl Chloride; Cooled; 20 Min,Rt; 3 H,Reflux2.1 Reagents: Sodium Bicarbonate Solvents: 1,4-Dioxane,Water; Cooled; 2 H,Cooled; Overnight,Rt3.1 Reagents: Sodium Hydroxide Solvents: Methanol,Water; 2 H,Reflux; Reflux -> Rt3.2 Reagents: Hydrochloric Acid Solvents: Water; Ph 14.1 Reagents: Pyridine,1,1′-Carbonyldiimidazole Solvents: Dimethylformamide; 2 H,45 °C4.2 Rt4.3 Reagents: Sodium Bicarbonate Solvents: Water5.1 Reagents: Acetic Acid; 2 H,Reflux; Cooled5.2 Reagents: Water6.1 Reagents: Hydrogen Catalysts: Palladium Solvents: Methanol; 3 H,207 Kpa,Rt
    标题:Improved Synthesis Of Parp Antagonist Veliparib
    作者:Lu,Tian-Xiang; Et Al
    参考文献:Zhongguo Yaowu Huaxue Zazhi 日期:2013 卷标:23(6) 页码:476-479]

    344-25-2 = 912444-00-9
    反应条件:1.1 Solvents: Chloroform; 8 H,Reflux2.1 Reagents: Lithium Diisopropylamide Solvents: Tetrahydrofuran; -78 °C; 4 H,-78 °C; -78 °C -> Rt2.2 Reagents: Water3.1 Reagents: Thionyl Chloride; Cooled; 20 Min,Rt; 3 H,Reflux4.1 Reagents: Sodium Bicarbonate Solvents: 1,4-Dioxane,Water; Cooled; 2 H,Cooled; Overnight,Rt5.1 Reagents: Sodium Hydroxide Solvents: Methanol,Water; 2 H,Reflux; Reflux -> Rt5.2 Reagents: Hydrochloric Acid Solvents: Water; Ph 16.1 Reagents: Pyridine,1,1′-Carbonyldiimidazole Solvents: Dimethylformamide; 2 H,45 °C6.2 Rt6.3 Reagents: Sodium Bicarbonate Solvents: Water7.1 Reagents: Acetic Acid; 2 H,Reflux; Cooled7.2 Reagents: Water8.1 Reagents: Hydrogen Catalysts: Palladium Solvents: Methanol; 3 H,207 Kpa,Rt
    标题:Improved Synthesis Of Parp Antagonist Veliparib
    作者:Lu,Tian-Xiang; Et Al
    参考文献:Zhongguo Yaowu Huaxue Zazhi 日期:2013 卷标:23(6) 页码:476-479
在 溶剂黄146体系中,用 水 作为反应溶剂,化学反应 6.0H,以77.5%的收率获得产物2-[(2R)-2-甲基-2-吡咯烷基]-1H-苯并咪唑-7-甲酰胺
参考文献:一种制备(R)-2-(2-甲基吡咯烷-2-基)-1H-苯并咪唑-4-甲酰胺的方法
标题:一种制备(R)-2-(2-甲基吡咯烷-2-基)-1H-苯并咪唑-4-甲酰胺的方法
摘要:本发明涉及一种制备(R)‑2‑(2‑甲基吡咯烷‑2‑基)‑1H‑苯并咪唑‑4‑甲酰胺的方法,该方法不仅避免使用三氟乙酸等强酸,而且简化了现有制备工艺,减少了污染,降低了成本,提高了产品纯度和收率.

海关参考信息

专利信息


专利号:US-12391691-B2
优先权日:2018-11-16
标题:Synthesis of key intermediate of KRAS G12C inhibitor compound
发明人:PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY
权利人:AMGEN INC
摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as

专利号:US-2025206736-A1
优先权日:2019-11-14
标题 :Synthesis of kras g12c inhibitor compound
发明人:CORBETT MICHAEL THOMAS; CAILLE SEBASTIEN
权利人:AMGEN INC
摘要:The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.

专利号:US-12043612-B2
优先权日:2020-05-09
标 题 :Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same
发明人:ALLAN LAURA E N; CHEN CHUNGPIN HERMAN; DONG HANQING; GROSSO JOHN A; HASKELL III ROYAL J; LLOYD RHYS; REECE HAYLEY
权利人:ARVINAS OPERATIONS INC
摘要:The present disclosure relates to ultra-pure forms, polymorphs, amorphous forms, and formulations of N-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]-6-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl}methyl)piperidin-1-yl]pyridazine-3-carboxamide, referred to herein as Compound A:The present disclosure also relates methods of manufacturing and purifying the same, as well as intermediates useful in the synthesis of Compound A. The ultra-pure forms, polymorphs, amorphous forms, and formulations of Compound A can be used as therapeutic agents for the treatment of various diseases and conditions such as cancer.

专利号:US-9993570-B2
优先权日:2014-01-05
标题:Radiolabeled tracers for poly (ADP-ribose) polymerase-1 (PARP-1), methods and uses therefor
发明人:MACH ROBERT; CHU WENHUA; ZHOU DONG; MICHEL LOREN; CHEN DELPHINE
权利人:UNIV WASHINGTON
摘要:Disclosed are PARP-1 inhibitors, which can be 18 F-labeled for use as tracers in positron emission tomographic (PET) imaging. Further disclosed are methods of synthesis. Of the compounds synthesized, 2-[p-(2-Fluoroethoxy)phenyl]-1.3.10-triazatricyclo[6.4.1.0 4,13 ]trideca-2,4(13),5,7-tetraen-9-one (12) had the highest inhibition potency for PARP-1 (IC 50 =6.3 nM). Synthesis of [ 18 F]-12 is disclosed under conventional conditions in high specific activity with 40-50% decay-corrected yield. MicroPET imaging using [ 18 F]-12 in MDA-MB-436 tumor-bearing mice demonstrated accumulation of [ 18 F]-12 in a tumor. Binding, can be blocked by olaparib. The compounds have utility for tumor imaging.

专利号:US-9598418-B2
优先权日:2012-12-31
标 题:Substituted phthalazin-1 (2H)-one derivatives as selective inhibitors of poly (ADP-ribose) polymerase-1
发明人:SRIVASTAVA BRIJESH K; DESAI RANJIT C; PATEL PANKAJ R
权利人:CADILA HEALTHCARE LTD
摘要:The present invention relates to novel compounds of general formula (I), their stereoisomers, regioisomers, tautomeric forms and novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. The present invention also relates to a process of preparing novel compounds of general formula (I), their stereoisomers, regioisomers, their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis.

专利号:WO-2023143427-A1
优先权日:2022-01-27
标题 :Crystal form of arv-110 and preparation method therefor and use thereof
发明人:SHENG XIAOXIA; SHENG XIAOHONG; CAO YAQING
权利人:HANGZHOU SOLIPHARMA CO LTD
摘要:The present application relates to the field of drug synthesis, in particular to a crystal form of ARV-110 and a preparation method therefor and a use thereof. The crystal form of the ARV-110 at least has one of the following improved characteristics: the stability is good, the hygroscopicity is low, the solubility is good, the melting point is high, stable storage can be achieved, crystal transformation of a drug in a development process and storage is avoided, the preparation method is simple and reliable, and great development values are achieved.
上海常丰生物医药科技有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.chainpharm.com
企业联系电话:021-61727342👤
📞上海常丰生物医药科技有限公司 ⚠️参考联系方式
联系人:张经理
电话:021-61727342
手机:13611721451
传真:021-33275302
邮箱:sales@chainpharm.com
通信地址: 上海金山区金瓯路188号
邮编: 201512
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:上海金山区金瓯路188号
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
台州市科瑞生物技术有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.pharm-intermediates.com
企业联系电话:0576-88813233👤
📞台州市科瑞生物技术有限公司 ⚠️参考联系方式
联系人:金崇光
电话:0576-88813233
手机:13396860566
传真:0576-88813233
邮箱:sales@pharm-intermediates.com
通信地址: 台州市开发大道东段288号
邮编: 318000
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:台州市开发大道东段288号
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
杭州科耀医药科技有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.searchem.net
企业联系电话:0571-58120272;17185714011;13067805092👤
📞杭州科耀医药科技有限公司 ⚠️参考联系方式
联系人:黄经理
电话:0571-58120272;17185714011;13067805092
手机:17185714011;13067805092
传真:0571-58120272
邮箱:sales@search.com
通信地址: 杭州下沙21号大街600号海创园5号楼四楼(西)
邮编: 310000
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:杭州下沙21号大街600号海创园5号楼四楼(西)
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
第 1 / 1 页

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: George RR, Thomas R, Davice A, Mathew MS. Veliparib for the treatment of solid malignancies. J Oncol Pharm Pract. 2022 Jun;28(4):924-934. doi: 10.1177/10781552221073990. Epub 2022 Jan 17. 33(4):384-394. doi: 10.1016/j.annonc.2022.01.009. Epub 2022 Jan 31. 42(3):260-273. doi: 10.1080/07357907.2024.2338128. Epub 2024 Apr 8. 15(17):1975-1987. doi: 10.2217/fon-2018-0883. Epub 2019 May 10. 19(4):497-509. doi: 10.1016/S1470-2045(18)30111-6. Epub 2018 Feb 28. 381(25):2403-2415. doi: 10.1056/NEJMoa1909707. Epub 2019 Sep 28.
7: Boussios S, Karihtala P, Moschetta M, Abson C, Karathanasi A, Zakynthinakis- Kyriakou N, Ryan JE, Sheriff M, Rassy E, Pavlidis N. Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach. Invest New Drugs. 2020 Feb;38(1):181-193. doi: 10.1007/s10637-019-00867-4. Epub 2019 Oct 24. 10(12):1637-1644. doi: 10.1001/jamaoncol.2024.4361. Erratum in: JAMA Oncol. 2024 Dec 1;10(12):1736. doi: 10.1001/jamaoncol.2024.6238. Erratum in: JAMA Oncol. 2025 Apr 1;11(4):435. doi: 10.1001/jamaoncol.2025.0254.
9: O'Reilly EM, Lee JW, Zalupski M, Capanu M, Park J, Golan T, Tahover E, Lowery MA, Chou JF, Sahai V, Brenner R, Kindler HL, Yu KH, Zervoudakis A, Vemuri S, Stadler ZK, Do RKG, Dhani N, Chen AP, Kelsen DP. Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation. J Clin Oncol. 2020 May 1;38(13):1378-1388. doi: 10.1200/JCO.19.02931. Epub 2020 Jan 24.

合成参考文献


参考文献:10.4161/cbt.7.6.5933
摘要:Liu X, Luo X, Shi Y, Zhu GD, Penning T, Giranda VL, Luo Y. Poly (ADP-ribose) polymerase activity regulates apoptosis in HeLa cells after alkylating DNA damage. Cancer Biol Ther. 2008 Jun;7(6):934–41. doi: 10.4161/cbt.7.6.5933.
参考文献:10.1007/s10555-008-9140-0
摘要:Dhani N, Siu LL. Clinical trials and biomarker development with molecularly targeted agents and radiotherapy. Cancer Metastasis Rev. 2008 Sep;27(3):339–49. doi: 10.1007/s10555-008-9140-0.
参考文献:10.1158/0008-5472.can-11-0814
摘要:Huehls AM, Wagner JM, Huntoon CJ, Geng L, Erlichman C, Patel AG, Kaufmann SH, Karnitz LM. Poly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells. Cancer Res. 2011 Jul 15;71(14):4944–54.
参考文献:10.3892/ijo.2012.1740
摘要:Feng X, Koh DW. Inhibition of poly(ADP-ribose) polymerase-1 or poly(ADP‑ribose) glycohydrolase individually, but not in combination, leads to improved chemotherapeutic efficacy in HeLa cells. Int J Oncol. 2013 Feb;42(2):749–56.
参考文献:10.1007/s00280-014-2486-9
摘要:Plummer R, Stephens P, Aissat-Daudigny L, Cambois A, Moachon G, Brown PD, Campone M. Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 2014 Jun 01;74(2):257–65. doi: 10.1007/s00280-014-2486-9.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知